Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Compounding And Medspa topic
No spam. Unsubscribe anytime.
Long testimony leaves compounding and med‑spa bill unresolved as committee holds SB 282
Summary
The committee paused action on SB 282 after hours of competing testimony: public‑health advocates urged strict sourcing and certificates of analysis for compounding ingredients; compounding pharmacists and patient advocates warned the bill as written could block access and raise costs for vulnerable patients and pets.
Senate Bill 282, which would set new sourcing and testing rules for bulk drug substances used in compounding products and add oversight for medical spas, prompted the longest and most contentious testimony of the day. Safety advocates described a "Wild West" in which some compounding ingredients arrive from facilities never inspected by the FDA and in some cases contain non‑human‑grade or ineligible substances.
Shabir Imberseftar (Partnership for Safe Medicines) told the committee that recent FDA warning letters and import freight data show a growing volume of APIs and ingredients manufactured in non‑FDA‑registered facilities. He urged statutory requirements that wholesalers and compounders obtain assurance that APIs were produced in FDA‑registered facilities and be accompanied by a certificate of analysis (COA).
Manufacturers, patient‑safety experts and life‑sciences trade groups echoed concerns about illicit supply chains and unfair competition that undercuts FDA‑regulated manufacturers. They argued that minimal documentation and verification requirements would protect patients and Indiana jobs.
Compounding pharmacists and small‑business owners pushed back, saying most licensed compounding pharmacies already obtain COAs and follow United States Pharmacopeia (USP) standards; they cautioned the bill's current drafting could prevent pharmacies from sourcing commonly used vitamins, minerals, flavors and other excipients, disrupting care for children, pets and patients with special needs. Several witnesses described patient stories in which personalized compounded medicines were clinically necessary.
Several parties recommended additional work with the Board of Pharmacy and stakeholder groups to harmonize statutory text with USP standards and avoid unintended market consequences. After lengthy debate, the chair said the committee would hold SB 282 for a week to review testimony and draft changes; no formal vote was taken.
